Innovative method to diagnose Coronary Cameral fistula by contrast echocardiography

Moustafa Eldeib¹, Fatema Qaddoura², Marawan Sadek², Reda Abuelatta³, and Ayman Naguib⁴

¹Al-Azhar University Faculty of Medicine
²King Fahd Military Medical Complex
³Madinah Cardiac Center
⁴Zagazig University

August 22, 2020

Abstract

Introduction: Coronary artery fistula (CAF) is a rare cardiac anomaly that typically presents as a continuous murmur in an otherwise asymptomatic patient. Occasionally, it can result in congestive heart failure or bacterial endocarditis. Objective: To better delineate the course of coronary artery fistula using an intracoronary injection of SonoVue contrast agent, whilst performing transthoracic echocardiography. Method and results: A referred 46-year-old male, with a history of exertional dyspnea for almost three months, was admitted to the hospital with progressive dyspnea, and assessed under suspicion of CAF. CAF was seen with a coronary angiogram, but the exact entry point in the left ventricle or left atrial wall could not be determined. CT angiography also failed to establish the drainage site, so CAG (coronary angiography) was repeated with the SonoVue contrast agent injected into LM (Left main) while using a Siemens echocardiography machine. Multiple views were obtained during the injection and revealed unusual flow in the left ventricle just below the PML (posterior mitral leaflet) and passing through the fistula to LV. Conclusion: Contrast-Enhanced Echocardiography by direct intracoronary injection of SonoVue contrast agent, is safe and can aid in the delineation of fistula drainage.

Introduction

Congenital CAF is an uncommon cardiac anomaly that usually presents with a continuous murmur in otherwise asymptomatic patients (1). Occasionally, it leads to congestive heart failure or bacterial endocarditis (1-3). If fistulas remain undetected or untreated in childhood, they reportedly (1, 3) become symptomatic more frequently in adulthood due to chronic volume overload and myocardial ischemia. Although spontaneous closure can occur sporadically (4, 5), Among the treatment options, an elective surgical closure (1, 3, 6, 7) or percutaneous closure in the cardiac catheterization laboratory. To enable successful and safe closure, it is imperative to define the anatomy of the fistula. (15)

A large fistula can occasionally appear as a mass lesion on echocardiography, the course of the fistula can be difficult to confirm by echocardiography. Here, we report a new diagnostic approach to identifying CAF, using an intracoronary injection of SonoVue contrast agent, whilst performing transthoracic echocardiography.

CASE REPORT

A 46-year-old male was admitted to the hospital with progressive dyspnea. He reported suffering from dyspnea upon exertion for 3 months and had been referred from another hospital for further review due to suspicion of coronary fistula, which was present on a coronary angiogram. It had previously not been
possible to determine the drainage site. No abnormal findings had been observed using an initial chest posterior-anterior view and electrocardiogram.

**Investigations:** Transthoracic and trans-esophageal echocardiography revealed severe LV systolic dysfunction, moderate MR (Mitral Regurgitation) (Figure 1), and with agitated saline small PFO (patent foramen ovale) was observed with TEE (Trans-Esophageal Echocardiography) between the LA (Left Atrium) and the RA (Right Atrium) (Figure 2).

CT angiography was performed, but the results non informative about the drainage site.

Therefore, a further coronary angiogram was performed (figure 3) using the SonoVue contrast agent (injection of 1.0 ml SonoVue diluted with 9.0 ml normal saline, and injected into LM), at the same time as using a Siemens echocardiography machine. Multiple views were obtained with the injection and found flow in the left ventricle just below the PML passing through fistula to LV (figures 4) and at the systolic phase with MR to LA and through PFO to RA and RV.

**Treatment:** After heart team discussion and given symptoms of heart failure attributed to a hemodynamically significant shunt, the decision was made to close it. The antegrade approach was used with percutaneous closure with coils (figure 5). Immediately after closure, the patient’s MR improved (figure 6).

**Discussion**

A CAF is defined as an abnormal communication between one of the coronary arteries and a cardiac chamber or another blood vessel. CAFs are present in 0.2% of patients undergoing diagnostic cardiac catheterization.

The right and left coronary arteries are involved in 55 and 35% of cases, respectively, with the involvement of both vessels in just 5% of cases. The arteries serve as a shunt between the coronary system and the cardiac chamber into which they drain. Large shunts may present with pulmonary edema, pulmonary hypertension, infective endocarditis, rupture, or thrombosis of the fistula, and associated arterial aneurysm or myocardial ischemia distal to the fistula (‘myocardial steal phenomenon’).

There are several possible reasons why CAF may not be visualized directly using transthoracic echocardiography. The CAF may be distally positioned in the coronary circulation and could be of smaller caliber. This can make them much more difficult to detect, particularly during ventricular systole. However, it is possible to visualize them with contrast when a higher MI (Mechanical Index) is used. This supports the visualization of both the myocardial tissue and the contrast agent simultaneously.

Contrast agents (including SonoVue) have been reported previously as safe for direct coronary artery injection. It has been used safely during septal ablation in patients with hypertrophic obstructive cardiomyopathy. These agents have a good safety profile for use in both cardiac and abdominal ultrasound applications. The incidence of severe adverse reactions to ultrasound contrast agents is no greater and may be lower than that reported for the contrast agents commonly used in other cardiac imaging tests.

Previously, CAF has been diagnosed with aortography, coronary angiography, and coronary CT. Although there has been a case of color Doppler assessment of a CAF, we cannot readily confirm them with echocardiography. In this study, we employed a new and simple diagnostic approach for CAF using a contrast agent. This assisted with the diagnosis, because it clarifies typical turbulence flow, as it appears in the left ventricle. The use of intraprocedural contrast echocardiography results in an improved procedure and thereby patient outcomes, by shortening the procedure and fluoroscopy time. Contrast echocardiography at the time of aortography proves extremely valuable in both opacifying the coronary arteries and determining which chambers the fistula connects to.

The value of localizing the site of drainage of the fistula is high to the interventional cardiologist when attempting to close it.

**Conclusion**
Contrast-Enhanced Echocardiography by intracoronary injection of SonoVue contrast agent is safe and can aid in the delineation of fistula drainage.

This research did not receive any specific grant from any funding agency in the public, commercial, or not-for-profit sector.

There is no conflict of interest.

The co-author confirms my findings and gave me permission and responsibility to report on the patient.

References:


Hosted file